MX392844B - Formas cristalinas del antagonista del receptor cxcr7 acido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3-carbonil]-amino}-piperidin-3-carboxilico (1-pirimidin-2-il-ciclopropil)-amida - Google Patents

Formas cristalinas del antagonista del receptor cxcr7 acido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3-carbonil]-amino}-piperidin-3-carboxilico (1-pirimidin-2-il-ciclopropil)-amida

Info

Publication number
MX392844B
MX392844B MX2020007881A MX2020007881A MX392844B MX 392844 B MX392844 B MX 392844B MX 2020007881 A MX2020007881 A MX 2020007881A MX 2020007881 A MX2020007881 A MX 2020007881A MX 392844 B MX392844 B MX 392844B
Authority
MX
Mexico
Prior art keywords
crystalline forms
cyclopropylmethyl
isoxazole
pyrimidin
difluoro
Prior art date
Application number
MX2020007881A
Other languages
English (en)
Other versions
MX2020007881A (es
Inventor
Raumer Markus Von
Philippe Guerry
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2020007881A publication Critical patent/MX2020007881A/es
Publication of MX392844B publication Critical patent/MX392844B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La solicitud se refiere a formas cristalinas de ácido (33.4S)-1-ciclopropilmetil-4-0-(2A-difluoro-fenil)-isoxazol-3-carbonill-amino)-piperidin-3-carboxílco (1-pirimidin-2-il-ciclopropil)-amida: procesos para la preparación de las mismas y composiciones farmacéuticas que condenen tales formas cristalinas. El compuesto actúa como modulador de receptor CXCR7 y así es útil para el tratamiento del cáncer.
MX2020007881A 2018-01-26 2019-01-25 Formas cristalinas del antagonista del receptor cxcr7 acido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3-carbonil]-amino}-piperidin-3-carboxilico (1-pirimidin-2-il-ciclopropil)-amida MX392844B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018051938 2018-01-26
PCT/EP2019/051819 WO2019145460A1 (en) 2018-01-26 2019-01-25 Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide

Publications (2)

Publication Number Publication Date
MX2020007881A MX2020007881A (es) 2022-06-02
MX392844B true MX392844B (es) 2025-03-24

Family

ID=65139016

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007881A MX392844B (es) 2018-01-26 2019-01-25 Formas cristalinas del antagonista del receptor cxcr7 acido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3-carbonil]-amino}-piperidin-3-carboxilico (1-pirimidin-2-il-ciclopropil)-amida

Country Status (25)

Country Link
US (1) US11339148B2 (es)
EP (1) EP3743422B1 (es)
JP (1) JP7076010B2 (es)
KR (1) KR102502046B1 (es)
CN (1) CN111683945B (es)
AU (1) AU2019212888B8 (es)
BR (1) BR112020015024A2 (es)
CA (1) CA3088478A1 (es)
CL (1) CL2020001928A1 (es)
EA (1) EA202091746A1 (es)
ES (1) ES2976567T3 (es)
HR (1) HRP20240552T1 (es)
HU (1) HUE066704T2 (es)
IL (1) IL276227B2 (es)
MA (1) MA51664B1 (es)
MX (1) MX392844B (es)
MY (1) MY206631A (es)
PH (1) PH12020551121A1 (es)
PL (1) PL3743422T3 (es)
RS (1) RS65594B1 (es)
SG (1) SG11202006943TA (es)
TW (1) TWI822724B (es)
UA (1) UA125327C2 (es)
WO (1) WO2019145460A1 (es)
ZA (1) ZA202005286B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45782B1 (fr) 2016-07-28 2021-12-31 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur de cxcr7 pipéridine
JP7749552B2 (ja) * 2019-10-31 2025-10-06 イドルシア・ファーマシューティカルズ・リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1565436B1 (en) 2002-11-27 2012-04-25 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
US7115646B2 (en) 2003-10-08 2006-10-03 Bristol Myers Squibb, Co. Cyclic diamines and derivatives as factor Xa inhibitors
JP4058106B2 (ja) 2005-02-18 2008-03-05 アストラゼネカ アクチボラグ 抗菌性のピペリジン誘導体
WO2009011850A2 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
JP6094578B2 (ja) 2011-06-09 2017-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン
WO2013084241A1 (en) 2011-12-09 2013-06-13 Cadila Healthcare Limited Compounds as inhibitors of renin
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
MX359651B (es) * 2012-11-29 2018-10-05 Chemocentryx Inc Antagonistas de cxcr7.
MA38679B1 (fr) 2013-05-30 2019-12-31 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur de cxcr7
CN105705489B (zh) 2013-09-04 2019-04-26 百时美施贵宝公司 用作免疫调节剂的化合物
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
US20170253601A1 (en) * 2014-09-10 2017-09-07 Epizyme, Inc. Substituted Pyrrolidine Compounds
CA2960280A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Substituted piperidine compounds
JP6582056B2 (ja) * 2014-12-01 2019-09-25 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｃｘｃｒ７受容体調節剤
MA45782B1 (fr) * 2016-07-28 2021-12-31 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur de cxcr7 pipéridine

Also Published As

Publication number Publication date
TW201932460A (zh) 2019-08-16
CL2020001928A1 (es) 2020-12-18
KR20200116115A (ko) 2020-10-08
IL276227B1 (en) 2024-06-01
WO2019145460A1 (en) 2019-08-01
IL276227A (en) 2020-09-30
SG11202006943TA (en) 2020-08-28
EP3743422C0 (en) 2024-03-13
CN111683945A (zh) 2020-09-18
AU2019212888B8 (en) 2024-01-04
RS65594B1 (sr) 2024-06-28
PH12020551121A1 (en) 2021-05-31
CA3088478A1 (en) 2019-08-01
ZA202005286B (en) 2025-02-26
CN111683945B (zh) 2023-11-10
MY206631A (en) 2024-12-27
AU2019212888B2 (en) 2023-12-21
HUE066704T2 (hu) 2024-08-28
JP7076010B2 (ja) 2022-05-26
EP3743422B1 (en) 2024-03-13
UA125327C2 (uk) 2022-02-16
MX2020007881A (es) 2022-06-02
US20210115033A1 (en) 2021-04-22
MA51664A (fr) 2021-05-05
KR102502046B1 (ko) 2023-02-20
AU2019212888A8 (en) 2024-01-04
JP2021511382A (ja) 2021-05-06
EP3743422A1 (en) 2020-12-02
HRP20240552T1 (hr) 2024-07-19
BR112020015024A2 (pt) 2021-01-19
EA202091746A1 (ru) 2020-11-26
ES2976567T3 (es) 2024-08-05
US11339148B2 (en) 2022-05-24
MA51664B1 (fr) 2024-05-31
PL3743422T3 (pl) 2024-07-01
IL276227B2 (en) 2024-10-01
TWI822724B (zh) 2023-11-21
AU2019212888A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
ZA202100208B (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
CR20200588A (es) Compuestos novedosos
WO2019191229A8 (en) Compounds for treating huntington's disease
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
EA201990851A1 (ru) Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
WO2018226622A8 (en) Compounds for treating huntington's disease
PH12022550286A1 (en) Deuterated compounds for use in the treatment of cancer
MX2024013464A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos
MX2020002399A (es) Inhibidores del enlace proteína-proteína de wdr5.
ZA202304541B (en) Cdk inhibitors and their use as pharmaceuticals
NZ762437A (en) Novel heterocyclic compounds as cdk8/19 inhibitors
MX2020012691A (es) Proceso para la sintesis del acido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxilico.
ZA202005286B (en) Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
EA200801777A1 (ru) α КРИСТАЛЛИЧЕСКАЯ ФОРМА АРГИНИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
MX2023011829A (es) Derivados de uracilo como inhibidores de trpa1.
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
UA98757C2 (ru) Бензамидные соединения, полезные как ингибиторы деацетилазы гистонов
MX2024014435A (es) Compuestos heterociclicos y heteroarilo para el tratamiento de la enfermedad de huntington
MX2024008371A (es) Compuestos organicos deuterados y usos de los mismos
EA202090995A1 (ru) Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1
MX2025013649A (es) Compuesto de oxazolona sustituida para reducir los niveles de proteinas con dedos de zinc ikaros (ikzf) 1-4
SA522441973B1 (ar) Trpa1 مشتقات تترازول كمثبطات لـ
MX2021001335A (es) Inhibidores de ckd8/19.
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4